Table 3.

GalNAc–siRNA conjugate based clinical studies, their targets, action and other details.

Drug	Condition	Target	Delivery/Mode	Phase	Status	Sponsors	Patents ID	Refs.
ARC-520	Chronic HBV infection	Surface proteins	Intravenous injections	II	Terminated	Arrowhead Pharmaceuticals	NCT02452528 NCT01872065 NCT02604212	[85]
	HBV infection	Surface proteins	subcutaneously	II	Terminated	Arrowhead Pharmaceuticals	NCT02577029 NCT02065336 NCT02604199	[85]
ARC-521	HBV infection	Viral DNA	subcutaneously	I	Terminated	Alnylam Pharmaceuticals	NCT02797522	[85]
DCR-HBVS	Hepatitis B	HBV gene	GalNAc–siRNA conjugate	I/II	–	Dicerna Pharmaceuticals	NCT03772249	[85]
ALN-HBV02 (VIR-2218)	Hepatitis B	HBV gene	GalNAc–siRNA conjugate	I/II	–	Alnylam Pharmaceuticals	NCT03672188 NCT02826018	[85]
AB-729	Hepatitis B	HBV gene	GalNAc–siRNA conjugate	Preclinical	–	Arbutus Biopharma Corporation	–	[86]
RBD1016	Hepatitis B	HBV gene	GalNAc–siRNA conjugate	Preclinical	–	Suzhou Ribo Life ScienceCo., Ltd	–	[86]
JNJ-3989(ARO-HBV)	Hepatitis B	HNV viral proteins	GalNAc–siRNA conjugate	II	Completed/ Terminated	Arrowhead/JNJ	NCT03365947 NCT03982186 NCT04129554	[85]
ARB-1467	Hepatitis B	HBV gene	LNP	IIa	Completed	Arbutus Biopharma Corporation	NCT02631096	[85]
TKM-130803	Ebola virus disease	Viral proteins	Intravenous infusion	II	Terminated	Arbutus Biopharma	PACTR201501000997429	[73]
TKM-100201 (TKM-EBOV-001)	Ebola virus disease	Viral proteins	Intravenous infusion	I	Terminated	Arbutus Biopharma Corporation	NCT01518881	[85]